Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1941-1946

  Talarico, Christine L ^a   Burnette, Thimysta C ^a   Miller, Wayne H ^a   Smith, Sheila L ^a   Davis, Michelle G ^a   Stanat, Sylvia C ^a   Ng, Teresa I ^b,d   He, Zuwen ^c   Coen, Donald M ^c   Roizman, Bernard ^b   Biron, Karen K ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; HERPES SIMPLEX VIRUS 1; HUMAN CYTOMEGALOVIRUS; PHOSPHORYLATION; PRIORITY JOURNAL; VIRUS RECOMBINANT;

EID: 0032838505     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1941     Document Type: Article

References (47)

1. Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800.
2. Baldanti, F., M. R. Underwood, C. L. Talarico, L. Simoncini, A. Sarasini, K. K. Biron, and G. Gerna. 1998. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents. Chemother. 42:444-446.
3. Balfour, H. H., Jr., B. A. Chace, J. T. Stapleton, R. L. Simmons, and D. S. Fryd. 1989. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allographs. N. Engl. J. Med. 320:1381-1387.
4. Biron, K. K., S. C. Stanat, J. B. Sorrell, J. A. Fyfe, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-{[2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl} guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:2473-2477.
5. Biron, K. K., J. A. Fyfe, S. C. Stanat, L. K. Leslie, J. B. Sorrell, C. U. Lambe, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl} guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. USA 83:8769-3773.
6. Boehme, R. 1984. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J. Biol. Chem. 259:12346-12349.
7. Chee, M. S., G. L. Lawrence, and B. G. Barrell. 1989. Alpha-, beta-, and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Microbiol. 70:1151-1160.
8. Cheng, Y. C., S. P, Grill, G. E. Dutschman, K. Nakayama, and K. F. Bastow. 1983. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J. Biol. Chem. 258:12460-12464.
9. Chou, S. C., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
10. Cole, N. L., and H. H. Balfour, Jr. 1987. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn. Microbiol. Infect. Dis. 6:255-261.
11. Drew, W. L., R. Anderson, W. Lang, R. C. Miner, G. Davis, and J. Lalezari. 1995. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:289-291.
12. Drew, W. L., W. Buhles, and K. S. Erlich. 1988. Herpesvirus infections (cytomegalovirus, herpes simplex virus, varicella zoster virus). How to use ganciclovir (DHPG) and acyclovir. Infect. Dis. Clin. N. Am. 2:495-509.
13. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follanbee, J. Gullet, S. G. Mahalko, A. M. Gordan, W. F. Owen, Jr., T. R. Matthews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of CMV resistance in patients receiving ganciclovir for serious CMV infection. J. Infect. Dis. 163:716-719.
14. Elion, G. B., P. A. Furman, J. A. Fyfe, P. de Miranda, L. Beauchamp, and H. J. Schaeffer. 1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 74:5716-5720.
15. Elkins, C. C., W. H. Frist, J. S. Dummer, J. R. Stewart, W. H. Merrill, K. A. Carden, and H. W. Bender. 1993. Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated? Ann. Thorac. Surg. 56:1267-1273.
16. Ertl, P., W. Snowden, D. Lowe, W. Miller, P. Collins, and E. Littler. 1995. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antivir. Chem. Chemother. 6:89-97.
17. Feinberg, J. E., S. Hurwitz, D. Cooper, F. R. Sattler, R. R. MacGregor, W. Powderly, G. N. Holland, P. D. Griffiths, R. B. Pollard, M. Youle, M. J. Gill, F. J. Holland, M. E. Power, S. Owens, D. Coakley, J. Fry, and M. A. Jacobson. 1998. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 177:48-56.
18. Field, A. K., M. E. Davies, D. DeWitt, H. C. Perry, R. Liou, J. Germenshausen, J. D. Karkas, W. T. Ashton, D. B. R. Johnston, and R. L. Tolman. 1983. 9-[(2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80:4139-4143.
19. Furman, P. A., M. H. St. Clair, J. A. Fyfe, J. L. Rideout, P. M. Keller, and G. B. Elion. 1979. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J. Virol. 32:72-77.
20. Furman, P. A., P. de Miranda, M. H. St. Clair, and G. B. Elion. 1981. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob. Agents Chemother. 20:518-524.
21. Fyfe, J. A., P. M. Keller, P. A. Furman, R. L. Miller, and G. B. Elion. 1978. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 253:8721-8727.
22. Glenn, J. 1981. Cytomegalovirus infections following renal transplantation. Rev. Infect. Dis. 3:1151-1178.
23. Griffiths, P. D., J. E. Feinberg, J. Fry, C. Sabin, L. Dix, D. Gor, A. Ansari, and V. C. Emery. 1998. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. J. Infect. Dis. 177:57-64.
24. Hamzeh, F. M., P. S. Lietman, W. Gibson, and G. S. Hayward. 1990. Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination. J. Virol. 64:6184-6195.
25. Hanson, M. N., L. C. Preheim, S. C. Chou, C. L. Talarico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205.
26. He, Z., and D. M. Coen. Personal communication.
27. He, Z., Y.-S. He, Y. Kim, L. Chu, C. Ohmstede, K. K. Biron, and D. M. Coen. 1997. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71:405-411.
28. Jacobson, M. A., J. Gallant, L. H. Wang, D. Coakley, S. Weller, D. Gary, L. Squires, M. L. Smiley, M. R. Blum, and J. Feinberg. 1994. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 38:1534-1540.
29. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
30. Littler, E., A. D. Stuart, and M. S. Chee. 1992. The human cytomegalovirus UL97 open reading frame encodes a protein which phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
31. Lurain, N. S., L. E. Spafford, and K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:4427-4431.
32. Mar, E-C., Y-C. Cheng, and E-S. Huang. 1983. Effect of 9-(1,3-dihydroxy-2-proxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24:518-521.
33. Marker, S. C., R. J. Howard, R. I. Simmons, et al. 1981. Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery 89:660-671.
34. McQuirt, P. V., and P. A. Furman. 1982. Acyclovir inhibition of viral DNA chain elongation in herpes simplex virus-infected cells. Am. J. Med. 73 (Suppl. 1A):67-71.
35. Metzger, C., D. Michel, K. Schneider, A. Lüske, H.-J. Schlicht, and T. Mertens. 1994. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J. Virol. 68:8423-8427.
36. Meyers, J. D., E. C. Reed, D. H. Shepp, et al. 1988. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 318:70-75.
37. Michel, D., I. Pavic, A. Zimmerman, E. Haupt, K. Wunderlich, M. Heuschmid, and T. Mertens. 1996. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346.
38. Ng, T. I., C. Talarico, T. C. Burnette, K. Biron, and B. Roizman. 1996. Partial substitution of the functions of the herpes simplex virus 1 UL13 gene by the human cytomegalovirus UL97 gene. Virology 225:347-358.
39. Nunan, T. O., M. King, P. Bull, J. E. Banatvala, N. F. Jones, and P. J. Hilton. 1984. Parenteral acyclovir therapy for cytomegalovirus infection after renal transplantation. Clin. Nephrol. 22:28-31.
40. Peterson, P. K., H. H. Balfour, S. C. Marker, D. S. Fryd, R. J. Howard, and R. L. Simmons. 1980. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 59:283-300.
41. Sha, B. E., C. A. Benson, T. A. Deutsch, P. A. Urbanski, J. P. Phair, and H. A. Kessler. 1991. Suppression of cytomegalovirus retinitis in persons with AIDS with high-dose intravenous acyclovir. J. Infect. Dis. 164:777-780.
42. Smee, D. F., J. C. Martin, J. P. Verheyden, and T. R. Matthews. 1983. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob. Agents Chemother. 23:676-682.
43. Snoeck, R., G. Andrei, and E. De Clercq. 1996. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 15:574-579.
44. Stanat, S. C., J. E. Reardon, A. Erice, M. C. Jordan, W. L. Drew, and K. K. Biron. 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:2191-2197.
45. Sullivan, V., and D. M. Coen. 1991. Isolation of foscarnet-resistant human cytomegalovirus: patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 164:781-784.
46. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
47. Zimmermann, A., D. Michel, I. Pavic, W. Hampl, A. Luske, J. Neyts, E. De Clercq, and T. Mertens. 1997. Phosphorylation of acyclovir, ganciclovir, penciclovir, and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antivir. Res. 36:35-42.